Sector News

Glenmark Pharma to divest 75% stake in life sciences unit for $680m

September 22, 2023
Life sciences

Glenmark Pharmaceuticals has signed a definitive agreement for the divestiture of a 75% stake in its division, Glenmark Life Sciences (GLS), to Indian company Nirma in a deal valued at Rs56.51bn ($679.85m).

Glenmark Life Sciences focuses on producing active pharmaceutical ingredients (API).

As per the deal, Glenmark Pharma is selling the stake in the life sciences unit for Rs615 for each share.

Following the divestiture, Glenmark Pharma will own a 7.84% stake in GLS.

Glenmark Pharmaceuticals chairman and managing director Glenn Saldanha said: “We are pleased to announce this strategic transaction with Nirma, which marks a significant milestone in shaping an independent growth trajectory for GLS.

“This deal aligns with our strategic intent of moving up the value chain to become an innovative/brand-led organisation, with continuous focus on our core therapeutic areas of dermatology, respiratory and oncology.

“It also presents an opportunity for us to strengthen shareholder value through deleveraging and enhancing our overall return profile.”

The conclusion of the deal is subject to necessary closing conditions and approvals from shareholders and regulators.

Following the deal closing, GLS will work as an independent API company under Nirma.

Furthermore, Nirma will make a compulsory open offer to all GLS public shareholders.

Glenmark Pharma continues to maintain growth across all its crucial markets while focusing on return ratios, eventually generating value for the shareholders of the company.

Kotak Investment Banking served as the exclusive financial adviser for Glenmark Pharma and GLS.

S&R Associates and Trilegal were the legal advisers to Glenmark Pharma and GLS, respectively.


comments closed

Related News

June 8, 2024

Lilly CFO leaves to join Alphabet

Life sciences

Anat Ashkenazi will leave Eli Lilly’s executive suite at the end of July to become CFO and senior vice president of Google and Alphabet. Ashkenazi has been CFO at Lilly since 2021 and originally joined the company in 2001. Over her 23-year career at the Indianapolis-based drugmaker, Ashkenazi also served as controller, CFO of Lilly Research Laboratories and as the finance chief for several global divisions within the company.

June 8, 2024

Edwards Lifesciences to cell Critical Care to BD

Life sciences

Edwards Lifesciences (NYSE: EW) announced it has entered into a definitive agreement to sell its Critical Care product group to BD (Becton, Dickinson and Company), in an all-cash transaction valued at $4.2 billion. With this agreement, Edwards is no longer pursuing the previously announced spin-off of Critical Care.

June 8, 2024

Danaher names Martin Stumpe as chief data and AI officer

Life sciences

The company, which owns diagnostics and life sciences businesses including Beckman Coulter and Cepheid, said the appointment reflects its increasing investment in AI as “a driving force for innovation and productivity.” Danaher is focused on AI by also spending on its internal capabilities and partnering with academic groups.

How can we help you?

We're easy to reach